High-dose furmonertinib plus bevacizumab in EGFR-mutant non-small cell lung cancer with brain metastases after resistance to third-generation EGFR-TKIs: A retrospective study
In this retrospective study, high-dose furmonertinib combined with bevacizumab demonstrated favorable intracranial and systemic activity with an acceptable safety profile in EGFR-mutant NSCLC patients with CNS metastases after resistance to third-generation EGFR-TKIs. These findings provide preliminary evidence supporting the potential clinical benefit of this chemotherapy-sparing strategy. Importantly, these findings warrant further validation in biomarker-stratified prospective trials to guide patient selection and optimize treatment outcomes.
Authors
- Yin Pan
- Kaijing Liu (ORCID: https://orcid.org/0000-0001-6778-8371)
- Likun Chen (ORCID: https://orcid.org/0000-0002-7158-3878)
- Mingjie Yu
- Jing Chen (ORCID: https://orcid.org/0000-0002-3297-9183)
- Hui Yu (ORCID: https://orcid.org/0000-0003-2288-4671)
- Meichen Li (ORCID: https://orcid.org/0000-0003-3201-045X)
Institutions
- Sun Yat-sen University (CN)
- Sun Yat-sen University Cancer Center (CN)
- State Key Laboratory of Oncology in South China
Publication Details
- Journal
- Translational Oncology
- Published
- 2025-08-18
- DOI
- https://doi.org/10.1016/j.tranon.2025.102500
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00